In addition, the elevated TPD52 expression also indicated a lower relapse-free survival in the four major breast cancer subtypes (basal-like, HER2-enriched, luminal A and luminal B) (Fig. S2). This evidence concerns the gene ERBB2 and breast carcinoma.